Cargando…

Pro-phagocytic function and structural basis of GPR84 signaling

GPR84 is a unique orphan G protein-coupled receptor (GPCR) that can be activated by endogenous medium-chain fatty acids (MCFAs). The signaling of GPR84 is largely pro-inflammatory, which can augment inflammatory response, and GPR84 also functions as a pro-phagocytic receptor to enhance phagocytic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuan, Wang, Yujing, Supekar, Shreyas, Cao, Xu, Zhou, Jingkai, Dang, Jessica, Chen, Siqi, Jenkins, Laura, Marsango, Sara, Li, Xiu, Liu, Guibing, Milligan, Graeme, Feng, Mingye, Fan, Hao, Gong, Weimin, Zhang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502086/
https://www.ncbi.nlm.nih.gov/pubmed/37709767
http://dx.doi.org/10.1038/s41467-023-41201-0
Descripción
Sumario:GPR84 is a unique orphan G protein-coupled receptor (GPCR) that can be activated by endogenous medium-chain fatty acids (MCFAs). The signaling of GPR84 is largely pro-inflammatory, which can augment inflammatory response, and GPR84 also functions as a pro-phagocytic receptor to enhance phagocytic activities of macrophages. In this study, we show that the activation of GPR84 by the synthetic agonist 6-OAU can synergize with the blockade of CD47 on cancer cells to induce phagocytosis of cancer cells by macrophages. We also determine a high-resolution structure of the GPR84-G(i) signaling complex with 6-OAU. This structure reveals an occluded binding pocket for 6-OAU, the molecular basis of receptor activation involving non-conserved structural motifs of GPR84, and an unusual G(i)-coupling interface. Together with computational docking and simulations studies, this structure also suggests a mechanism for the high selectivity of GPR84 for MCFAs and a potential routes of ligand binding and dissociation. These results provide a framework for understanding GPR84 signaling and developing new drugs targeting GPR84.